Brokerages Set BeyondSpring (BYSI) Price Target at $49.60

Share on StockTwits

Shares of BeyondSpring (NASDAQ:BYSI) have been assigned an average rating of “Buy” from the six research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $49.60.

Several research firms recently weighed in on BYSI. ValuEngine raised BeyondSpring from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Maxim Group reissued a “buy” rating and set a $52.00 price target on shares of BeyondSpring in a research report on Thursday, May 17th. HC Wainwright set a $60.00 price target on BeyondSpring and gave the company a “buy” rating in a research report on Tuesday, April 3rd. Finally, Zacks Investment Research raised BeyondSpring from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Thursday, April 5th.

BeyondSpring traded up $0.53, hitting $27.22, during trading hours on Friday, MarketBeat reports. 9,689 shares of the company’s stock traded hands, compared to its average volume of 12,109. The firm has a market capitalization of $601.28 million, a price-to-earnings ratio of -6.19 and a beta of 0.28. BeyondSpring has a twelve month low of $19.55 and a twelve month high of $48.49.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Tuesday, April 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). sell-side analysts anticipate that BeyondSpring will post -2.8 earnings per share for the current year.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply